SCHEMBL4452800

SCHEMBL4452800

Clc1cc[c]cc1-c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 1/20 0.54
CSNK2A1 P68400 2/20 0.36
CYP1A2 P05177 2/20 0.36
BACE1 P56817 1/20 0.34
CTRC Q99895 2/20 0.34
HSD11B1 P28845 1/20 0.34
ALDH1A1 P00352 5/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
BCL2L1 Q07817 1/20 0.33
TP53 P04637 1/20 0.33
ALPL P05186 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1560829 0.96 CYP2A6 (0.50) CYP2A6CSNK2A1CYP1A2BACE1CTRC
SCHEMBL2093448 0.83 CYP2A6 (0.54) CYP2A6CSNK2A1CYP1A2BACE1CTRC
SCHEMBL21723073 0.83 AHR (0.42) CYP2A6CYP1A2ALDH1A1HSD17B10NPC1
SCHEMBL27555403 0.81 CYP2A6 (0.52) CYP2A6CSNK2A1CYP1A2BACE1CTRC
SCHEMBL27707558 0.80 TDO2 (0.40) NPC1RAB9ATP53SMN1; SMN2MAOB
SCHEMBL4420759 0.80 CYP2A6 (0.44) CYP2A6HSD11B1ALDH1A1HPGDHSD17B10
SCHEMBL618853 0.79 BACE1 (0.39) CYP2A6BACE1ALDH1A1HPGDHSD17B10
SCHEMBL8036356 0.79 MAPK1 (0.33) CYP2A6CYP1A2ALDH1A1TP53CYP3A4
SCHEMBL27707568 0.77 MAPK10 (0.39) CYP1A2ALDH1A1HPGDHSD17B10NPC1
SCHEMBL1691864 0.77 CYP2A6 (0.47) CYP2A6CYP1A2ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102459167-B Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV 2015-04-01 CN claimed
CN-115950965-A Non-targeted screening and identification method for effect component in organic component of atmospheric fine particulate matter 山西大学 2023-04-11 CN disclosed
CN-102459167-B Azetidinyl diamides as monoacylglycerol lipase inhibitors JANSSEN PHARMACEUTICA NV 2015-04-01 CN disclosed
EP-2684871-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives F. Hoffmann-La Roche AG (CH) 2014-01-15 EP disclosed
US-8513425-B2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2013-08-20 US disclosed
CN-101563319-B Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE 2012-09-05 CN disclosed
US-8084623-B2 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents ROCHE PALO ALTO LLC (US) 2011-12-27 US disclosed
CN-101563319-A Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE (CH) 2009-10-21 CN disclosed
EP-2102157-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-09-23 EP disclosed
US-7449477-B2 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B) ELI LILLY AND COMPANY (US) 2008-11-11 US disclosed
WO-2008074703-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed
CN-100391943-C Prepn. of 3-position substituted indole derivative UNIV ZHEJIANG (CN) 2008-06-04 CN disclosed
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms ELI LILLY AND COMPANY 2007-02-15 US disclosed
CN-1834089-A Prepn. of 3-position substituted indole derivative UNIV ZHEJIANG (CN) 2006-09-20 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR CYP2A6 386/4885CSNK2A1 997/4885CYP1A2 67/4885
US-20070037796-A1 e.g. 7-Phenyl-isoquinoline-5-sulfonic acid {2-[3 -(4-nitrophenyl)-propylamino]-ethyl}-amide, dihydrochloride salt; antiviral, antineoplastic, anticarcinogenic agents; neoplasms POLI, HRAS, CHUK CYP2A6 2400/4885CSNK2A1 1123/4885CYP1A2 3301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.